Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ATG7 | O95352 | 10/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14544500 | 0.81 | ABL1 (0.44) | CYP1A2PRMT5ALDH1A1LMNAALB | |
| SCHEMBL1795315 | 0.81 | ATG7 (0.52) | CA2ATG7 | |
| SCHEMBL12566870 | 0.78 | ATG7 (0.43) | CA2PRMT5BCHEATG7WDR77 | |
| SCHEMBL13773407 | 0.77 | CA2 (0.43) | CYP1A2CA2ATG7ALDH1A1LMNA | |
| SCHEMBL23892436 | 0.75 | PRMT5 (0.47) | PRMT5WDR77 | |
| SCHEMBL18572554 | 0.75 | PRMT5 (0.47) | PRMT5WDR77 | |
| SCHEMBL12652426 | 0.75 | ATG7 (0.46) | CA2PRMT5ATG7WDR77 | |
| SCHEMBL13773372 | 0.74 | BCHE (0.54) | CYP1A2BCHEALDH1A1LMNAALB | |
| SCHEMBL14563561 | 0.74 | NAE1 (0.53) | CA2 | |
| SCHEMBL12567150 | 0.73 | BCHE (0.47) | CYP1A2BCHEATG7ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | CYP1A2 644/4885CA2 3826/4885PRMT5 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.